White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 29, 2026.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience.
Show more
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience. The company's products include Opdivo for various anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumorsr; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag for the treatment of unresectable or metastatic melanoma; and Camzyos to treat symptomatic obstructive HCM. It also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for a reduction in risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane for the treatment of breast cancer. Further, it provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; and NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. Bristol-Myers Squibb Company has a strategic collaboration with Arcus Biosciences, Inc. to develop a novel treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.
Bristol-Myers Squibb Company (BMYB34) currently trades at R$331.90, while our model-based Fair Value estimate is R$358.85, so the stock looks roughly fairly valued today (gap 7.5%).
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of R$445.29 per share, and 15 of the 26 models we run sit above the R$331.90 price.
Bear case: the Economic Profit group reads lowest at R$128.08, and 11 of the 26 models stay below the price. Evidence for this calculation is high.
Scenario range: R$240.23 (bear) to R$470.72 (bull), the price of R$331.90 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 74/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Bristol-Myers Squibb Company reported revenue of $48.2B in FY2025 versus $46.4B in FY2021, a compound +1.0%/yr. Reported net income was $7.1B in FY2025, compounding +0.2%/yr from FY2021.
Key figures
Market cap R$676B (≈ $129B) · P/E ratio 17.9 · P/S ratio 2.62 · EPS (TTM) R$18.51 · Dividend yield 0.8% · Net margin 14.6% · Return on equity 38.7% · Return on assets (EBIT) 6.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 56 out of 100 (low confidence).
What moves the price
The share trades about 5% below its 52-week high and 48% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −1% fair-value upside, at 8%, BMYB34 screens cheaper than that median.
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (R$12.11 per share) are deliberately not added.
Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.
Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF
R$350.91
R$619.29
R$1,043
78
Growth DCF
R$355.71
R$588.03
R$929.25
77
Owner Earnings
R$258.22
R$469.34
R$802.66
74
All 26 models by family
DCF Models
FCF DCF
R$350.91
R$619.29
R$1,043
78
Owner Earnings
R$258.22
R$469.34
R$802.66
74
5Y Revenue Exit
R$217.58
R$378.16
R$581.94
71
5Y EBITDA Exit
R$293.05
R$522.96
R$793.58
74
5Y P/E Exit
R$240.79
R$422.69
R$615.37
70
10Y Revenue Exit
R$253.42
R$413.94
R$630.03
66
10Y EBITDA Exit
R$309.59
R$515.87
R$795.42
67
10Y P/E Exit
R$275.93
R$445.29
R$656.15
63
Earnings-Based
Graham-Dodd
R$122.67
R$429.33
R$577.29
64
Lynch FV
R$100.01
R$142.87
R$185.74
61
PEG = 1.0
R$100.01
R$142.87
R$185.74
57
EPV
R$135.63
R$172.15
R$204.10
74
Dividend Discount
Gordon GGM
R$118.46
R$246.31
R$390.74
66
DDM Multi-Stage
R$118.46
R$207.02
R$258.51
66
Multiples
P/E Multiple
R$297.65
R$396.87
R$496.09
63
P/S Multiple
R$230.00
R$306.67
R$383.34
58
P/B Multiple
R$159.44
R$212.59
R$265.74
55
EV/EBIT
R$254.46
R$367.10
R$479.74
65
EV/EBITDA
R$302.53
R$431.19
R$559.86
67
EV/Revenue
R$157.72
R$261.08
R$364.45
52
Asset-Based
NCAV (Graham)
R$23.62
R$31.65
R$47.24
54
Growth DCF
Growth DCF
R$355.71
R$588.03
R$929.25
77
Rev-Margin DCF
R$217.58
R$380.60
R$575.33
71
Economic Profit
Residual Income
R$101.18
R$128.08
R$231.43
73
ROIC Compounder
R$153.90
R$222.73
R$306.77
71
Growth Earnings
Growth-Adj P/E
R$255.27
R$364.68
R$474.08
67
Open the full fair value analysis →
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
10 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate.
Pick a strategy and jump into the live analysis with that exact screen applied.
Is Bristol-Myers Squibb Company (BMYB34) overvalued or undervalued?
As of Sep 29, 2026, our model estimates a fair value of R$358.85 versus a price of R$331.90, about +8% upside (fairly valued).
What is the fair value of BMYB34?
Our model-based fair value for Bristol-Myers Squibb Company is R$358.85 (as of Sep 29, 2026), built from audited fundamentals. The current price: R$331.90.
What is the quality score of BMYB34?
Bristol-Myers Squibb Company has a Quality Score of 74/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Bristol-Myers Squibb Company (BMYB34)?
Our model-based price target is the fair value of R$358.85 (as of Sep 29, 2026) from 26 valuation models. Cautious scenario R$240.23, optimistic scenario R$470.72. It is a calculation from audited fundamentals, not an analyst target.
What is the Bristol-Myers Squibb Company stock forecast for 2026?
Our models put fair value at R$358.85, about +8% upside versus a price of R$331.90 (fairly valued). Cautious scenario R$240.23, optimistic scenario R$470.72. The calculation is refreshed regularly with new filings.
What is the revenue of Bristol-Myers Squibb Company (BMYB34)?
Bristol-Myers Squibb Company reported trailing-twelve-month revenue of about $48.5B (latest available figure, as of Sep 29, 2026).
Does Bristol-Myers Squibb Company pay a dividend?
Bristol-Myers Squibb Company currently shows a dividend yield of about 0.75% relative to its recent price (as of Sep 29, 2026).
What growth is priced into Bristol-Myers Squibb Company (BMYB34)?
For today's price to be fair in a discounted-cash-flow model, Bristol-Myers Squibb Company would have to grow free cash flow by +3.7 % per year for five years (discount rate 10.7 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +2.5 % per year. As of Sep 29, 2026.
What discount rate (WACC) does the fair value of BMYB34 use?
Our models discount Bristol-Myers Squibb Company at 10.7 %: a base by market capitalisation (large), damped by beta 0.24, country premium for Brazil. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Bristol-Myers Squibb Company that is +3.7 % per year a year over ten years, using the same discount rate (10.7 %) and the same formula as our fair value.
How much growth has Bristol-Myers Squibb Company (BMYB34) delivered so far?
Over the past 5 years revenue at Bristol-Myers Squibb Company grew +2.5 % a year. The price currently implies +3.7 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Bristol-Myers Squibb Company (BMYB34) growing?
The median revenue growth in the sector is +5.1 % a year. That is the yardstick for the growth priced into Bristol-Myers Squibb Company (+3.7 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Bristol-Myers Squibb Company (BMYB34)?
The free-cash-flow yield on the price is 9.93 %: that much free cash flow Bristol-Myers Squibb Company produces per unit of market value. When it exceeds the discount rate of our models (10.7 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Bristol-Myers Squibb Company (BMYB34)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Bristol-Myers Squibb Company it is R$358.85 per share (as of Sep 29, 2026), against a price of R$331.90. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Bristol-Myers Squibb Company stock overvalued or undervalued in 2026?
As of Sep 29, 2026, BMYB34 trades below its calculated fair value: price R$331.90, fair value R$358.85, a gap of about +8% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BMYB34?
No. The price is what the market pays today (R$331.90); the fair value is what the company's own numbers justify (R$358.85). For Bristol-Myers Squibb Company the two are R$26.95 per share apart. That gap is exactly why we show both numbers side by side.
How much is Bristol-Myers Squibb Company worth?
The market values Bristol-Myers Squibb Company at about R$676B (market capitalisation, as of Sep 29, 2026). Per share that is R$331.90; our models calculate a fair value of R$358.85 per share.
What do the bullish and bearish scenarios say about BMYB34?
Our models span a range for Bristol-Myers Squibb Company: cautious scenario R$240.23, base R$358.85, optimistic R$470.72 per share (as of Sep 29, 2026, price R$331.90). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is BMYB34 from its 52-week high?
Bristol-Myers Squibb Company trades at R$331.90, about 5% below its 52-week high of R$349.41 and 48% above the low of R$224.60 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of R$358.85 is for.
Which stocks are comparable to Bristol-Myers Squibb Company?
From the same area (Healthcare) we also value Eli Lilly and Company, Johnson & Johnson,, AbbVie Inc, Roche Holding, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Bristol-Myers Squibb Company stock attractive at the current price?
The data as of Sep 29, 2026: price R$331.90, calculated fair value R$358.85 (+8%), Quality Score 74/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BMYB34 calculated?
We run Bristol-Myers Squibb Company through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of R$358.85, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Bristol-Myers Squibb Company currently trades 8 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on
is it worth investing now.
What is the share price of Bristol-Myers Squibb Company (BMYB34)?
The closing price on Oct 1, 2026 was R$331.90. Our model-based fair value is R$358.85, about +8% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Bristol-Myers Squibb Company right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (R$240.23 to R$470.72) leaves room in how you read the outcome.
Key figures of Bristol-Myers Squibb Company
How large is the market capitalisation of Bristol-Myers Squibb Company (BMYB34)?
The market capitalisation of Bristol-Myers Squibb Company is R$676B (≈ $129B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/E ratio of Bristol-Myers Squibb Company (BMYB34)?
The price-to-earnings ratio of Bristol-Myers Squibb Company is 17.9. Price to earnings: how many years of current profit you pay for the stock. A P/E of 10 means ten years of profit.
What is the P/S ratio of Bristol-Myers Squibb Company (BMYB34)?
The price-to-sales ratio of Bristol-Myers Squibb Company is 2.62 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Bristol-Myers Squibb Company (BMYB34)?
Earnings per share at Bristol-Myers Squibb Company are R$18.51 (price ÷ EPS = P/E 17.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Bristol-Myers Squibb Company (BMYB34)?
The dividend yield of Bristol-Myers Squibb Company is 0.8% (payout 13.5%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Bristol-Myers Squibb Company (BMYB34)?
The net margin of Bristol-Myers Squibb Company is 14.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Bristol-Myers Squibb Company (BMYB34)?
The return on equity (ROE) of Bristol-Myers Squibb Company is 38.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Bristol-Myers Squibb Company (BMYB34)?
On an EBIT basis the return on assets of Bristol-Myers Squibb Company is 6.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Bristol-Myers Squibb Company (BMYB34)?
The operating margin of Bristol-Myers Squibb Company is 33.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Bristol-Myers Squibb Company (BMYB34)?
Revenue at Bristol-Myers Squibb Company is growing +2.6% versus a year earlier (3y avg +1.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Bristol-Myers Squibb Company (BMYB34)?
Earnings per share at Bristol-Myers Squibb Company are growing +9.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Bristol-Myers Squibb Company (BMYB34) carry?
The net debt of Bristol-Myers Squibb Company is $34.9B (fiscal year 2025, ≈ 2.7 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
